Dr. Novack publishes 400th paper
Research Milestone, July 2025 — Dr. Novack published his 400th scientific paper, marking a significant contribution to ophthalmology and vision science research…
Lead article on FDA regulation of ophthalmic drugs
Regulatory Affairs, June 2024 — Dr. Novack authored the lead article on FDA regulation of ophthalmic drugs in the American Journal of Ophthalmology…
Dr. Novack’s contributions to the Journal of Ocular Pharmacology and Therapeutics highlighted
Editorial Leadership, April 2024 — Dr. Novack’s ongoing contributions to the Journal of Ocular Pharmacology and Therapeutics highlight his leadership in the field…
Dr. Novack selected to be fellow of AOPT
Professional Recognition, June 2023 — Dr. Novack was selected as a Fellow of the Association for Ocular Pharmacology and Therapeutics (AOPT)…
Compounding of Low-Concentration Atropine for Myopia Control
Clinical Research, November 2022 — Dr. Novack co-authored a publication on low-concentration atropine for myopia control…
Dr. Novack honored by American Academy of Ophthalmology
Professional Honor, September 2022 — Dr. Novack was honored by the American Academy of Ophthalmology for his contributions to the field…
Value of medical writers discussed in top journal
In a recent article in JAMA Oncology on the use of surrogate endpoints in oncology, del Paggio et al identified industry funding for nearly all. They further highlighted the use of medical writers in papers published on this work to be of concern…
Client publishes 100th paper – PharmaLogic wrote the first one
Glaukos announced that 200 papers published on their glaucoma product, the iStent. . We’re pleased to say that Dr. Novack was the medical writer for lead authors Dr. Thomas Samuelson and L. Jay Katz on the first one, in Ophthalmology…
Off-label use: Article in the American Journal of Ophthalmology
Together with UC Davis Ophthalmology faculty member, Ala Moshiri, M.D., Ph.D., I published a commentary in the American Journal of Ophthalmology regarding the challenges to making off-label use of products a standard of care in retina therapies in ophthalmology…